Milder dystrophic phenotypes with higher myostatin levels such as myotonic dystrophy [36] could possibly benefit from myostatin inhibition and muscular dystrophies characterized by proximal weakness in larger muscle groups may be a candidate for local treatment by gene therapy, as previously demonstrated [176]. Here, MSTN is linked to muscular dystrophy.